Artisan Partners Limited Partnership Trims Holdings in Replimune Group, Inc. $REPL

Artisan Partners Limited Partnership reduced its stake in Replimune Group, Inc. by 9.5% in Q2, owning 511,371 shares worth $4.75 million. Replimune's stock opened at $9.20, with a market cap of $721.65 million. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and a price target of $9.75. Insider sales were also reported.

Artisan Partners Limited Partnership decreased its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 9.5% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 511,371 shares of the company's stock after selling 53,704 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.66% of Replimune Group worth $4,751,000 at the end of the most recent quarter.

Get Replimune Group alerts:

The Best AI for Picking Stocks, Ranked by Performance

Several other hedge funds also recently bought and sold shares of the company. Letko Brosseau & Associates Inc. purchased a new position in Replimune Group during the 2nd quarter valued at approximately $100,000. Candriam S.C.A. purchased a new stake in shares of Replimune Group during the 2nd quarter valued at approximately $1,594,000. Nan Fung Trinity HK Ltd. purchased a new position in Replimune Group in the second quarter valued at $4,325,000. Los Angeles Capital Management LLC purchased a new stake in Replimune Group during the 2nd quarter worth about $403,000. Finally, AlphaQuest LLC raised its stake in Replimune Group by 99.9% during the 2nd quarter. AlphaQuest LLC now owns 9,857 shares of the company's stock worth $92,000 after acquiring an additional 4,925 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

Replimune Group Stock Up 2.1%

NASDAQ:REPL opened at $9.20 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.31 and a current ratio of 6.31. The company has a market capitalization of $721.65 million, a price-to-earnings ratio of -2.66 and a beta of 0.80. Replimune Group, Inc. has a one year low of $2.68 and a one year high of $17.00. The stock has a 50-day simple moving average of $6.75 and a 200 day simple moving average of $7.40.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Sell-side analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on REPL shares. Leerink Partners raised shares of Replimune Group from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $3.00 to $13.00 in a research note on Monday, October 20th. JPMorgan Chase & Co. upgraded shares of Replimune Group from an "underweight" rating to a "neutral" rating and set a $11.00 price target on the stock in a research note on Monday, October 20th. Wedbush raised shares of Replimune Group from a "neutral" rating to an "outperform" rating and increased their price target for the stock from $4.00 to $18.00 in a report on Monday, October 20th. Piper Sandler raised Replimune Group from a "neutral" rating to an "overweight" rating and set a $13.00 price objective on the stock in a report on Monday, October 20th. Finally, HC Wainwright upgraded Replimune Group from a "neutral" rating to a "buy" rating and set a $12.00 target price on the stock in a research report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Replimune Group presently has a consensus rating of "Moderate Buy" and an average price target of $9.75.

Check Out Our Latest Stock Analysis on Replimune Group

Insider Buying and Selling at Replimune Group

In related news, insider Konstantinos Xynos sold 7,248 shares of the firm's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $65,956.80. Following the transaction, the insider directly owned 139,685 shares in the company, valued at approximately $1,271,133.50. This trade represents a 4.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Christopher Sarchi sold 5,208 shares of Replimune Group stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $47,392.80. Following the sale, the insider owned 123,088 shares in the company, valued at $1,120,100.80. This represents a 4.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 5.20% of the company's stock.

Replimune Group Company Profile

(Free Report)

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

Should You Invest $1,000 in Replimune Group Right Now?

Before you consider Replimune Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.

While Replimune Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here